Study reveals immune-modulatory mechanism of lurbinectedin in small-cell lung cancer

Researchers at the Icahn School of Medicine at Mount Sinai have identified the mechanism of action of a treatment for small-cell lung cancer (SCLC), one of the ... and the five-year survival rate is ... Read More

Lung Cancer Survival Is Improving, Though State Rates Vary

The national survival ... published “State of Lung Cancer” report is its fifth annual snapshot of lung cancer trends across the United States. The report focused on incidence, survival ... Read More

Imfinzi Approved for Limited-Stage Small Cell Lung Cancer

The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has ... Read More

Systemic Therapy for Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update Clinical Insights

Fig 2. Updated Recommendations. C, conditional; ECOG, Eastern Cooperative Oncology Group; L, low; LS, limited-stage; M, moderate; PS, performance status; S, strong ... Read More

New PROSPECT-lung trial launches to advance treatment options for operable non-small cell lung cancer

The highly anticipated PROSPECT-Lung trial has officially opened, marking a significant step forward in the quest to improve treatment strategies for patients with resectable non-small cell lung ... Read More

PROSPECT-Lung trial aims to improve treatment for patients with resectable non-small cell lung cancer

The highly anticipated PROSPECT-Lung trial has officially opened, marking a significant step forward in the quest to improve treatment strategies for patients with resectable non-small cell lung ... Read More

Lung cancer survival in Louisiana among worst in U.S., but new treatments can help

Louisiana residents have one of the highest lung cancer ... five survival rate,” said Weinzettle. “But the good news is we are seeing improvements across the board." Lung cancer remains ... Read More

Roche's TIGIT prospect fails another phase 3 lung cancer test

The phase 3 trial found adding the TIGIT candidate tiragolumab to Roche's approved checkpoint inhibitor had no effect on overall survival (OS) in non-small cell lung cancer (NSCLC). Investigators ... Read More

FDA OKs Imfinzi for Limited-Stage Small Cell Lung Cancer

Imfinzi was approved by the FDA for the treatment of adults with limited-stage small cell lung cancer without disease progression after chemotherapy and radiation. Read More